U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

INVOKANA® is now the only oral diabetes treatment approved to reduce the risk of these cardiovascular events Approval aligns with ADA and AACE treatment guidance and supports use of INVOKANA® across a broad range of patients TITUSVILLE, N.J.,... Biopharmaceuticals, Endocrinology, Cardiology, FDA Janssen Pharmaceutical, INVOKANA, canagliflozin, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news